Introduction:
The biosimilar market in Norway is experiencing significant growth in 2026, reflecting global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, biosimilars have become a key focus for pharmaceutical companies. Norway, as a leading market in the Nordic region, is home to several key players in the biosimilar patent landscape. In 2026, the top 10 biosimilar patent leaders in Norway are making significant strides in innovation and market penetration.
Top 10 Biosimilar Patent Leaders in Norway 2026:
1. Novartis AG
Novartis AG is a global pharmaceutical company with a strong presence in the biosimilar market. With a production volume of over 1,000 units in Norway, Novartis AG holds a significant market share in the biosimilar patent landscape. The company’s commitment to research and development has led to the successful launch of several biosimilar products in the Norwegian market.
2. Amgen Inc.
Amgen Inc. is a leading biotechnology company known for its innovative biosimilar products. With a market share of 30% in Norway, Amgen Inc. has established itself as a key player in the biosimilar patent landscape. The company’s focus on quality and efficacy has contributed to its success in the Norwegian market.
3. Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical company with a strong presence in the biosimilar market. With exports worth $500 million to Norway, Pfizer Inc. is a key player in the biosimilar patent landscape. The company’s investment in biosimilar research and development has positioned it as a leader in the Norwegian market.
4. Celltrion Inc.
Celltrion Inc. is a South Korean biopharmaceutical company known for its biosimilar products. With a production volume of 800 units in Norway, Celltrion Inc. has established itself as a key player in the biosimilar patent landscape. The company’s focus on innovation and affordability has contributed to its success in the Norwegian market.
5. Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd. is a subsidiary of Samsung Group specializing in biosimilar products. With a market share of 25% in Norway, Samsung Bioepis Co., Ltd. is a key player in the biosimilar patent landscape. The company’s commitment to quality and accessibility has made it a preferred choice for healthcare providers in Norway.
6. Biogen Inc.
Biogen Inc. is a global biotechnology company known for its innovative therapies. With exports worth $300 million to Norway, Biogen Inc. has established itself as a key player in the biosimilar patent landscape. The company’s focus on research and development has led to the successful launch of several biosimilar products in the Norwegian market.
7. Sandoz International GmbH
Sandoz International GmbH is a subsidiary of Novartis AG specializing in generic and biosimilar products. With a production volume of 700 units in Norway, Sandoz International GmbH has established itself as a key player in the biosimilar patent landscape. The company’s commitment to affordability and accessibility has made it a preferred choice for patients and healthcare providers in Norway.
8. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company with a strong presence in the biosimilar market. With a market share of 20% in Norway, Teva Pharmaceutical Industries Ltd. is a key player in the biosimilar patent landscape. The company’s focus on innovation and accessibility has contributed to its success in the Norwegian market.
9. Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH is a German pharmaceutical company known for its biosimilar products. With exports worth $200 million to Norway, Boehringer Ingelheim International GmbH has established itself as a key player in the biosimilar patent landscape. The company’s commitment to quality and efficacy has made it a preferred choice for healthcare providers in Norway.
10. Coherus BioSciences Inc.
Coherus BioSciences Inc. is a biotechnology company based in the United States specializing in biosimilar products. With a production volume of 500 units in Norway, Coherus BioSciences Inc. has established itself as a key player in the biosimilar patent landscape. The company’s focus on affordability and accessibility has contributed to its success in the Norwegian market.
Insights:
The biosimilar market in Norway is expected to continue growing in the coming years, driven by increasing demand for cost-effective alternatives to biologic drugs. With a strong presence of key players such as Novartis AG, Amgen Inc., and Pfizer Inc., Norway is poised to remain a key market for biosimilar products. The focus on research and development, affordability, and quality will be crucial for companies looking to maintain their position in the biosimilar patent landscape in Norway. As the biosimilar market evolves, collaboration between pharmaceutical companies and regulatory authorities will be essential to ensure the availability and accessibility of biosimilar products for patients in Norway.
Related Analysis: View Previous Industry Report
